With a market capitalization (market cap) of $2.52B — a measure of how much the company is worth — Pharvaris N.V. is the 1936th most valuable company in Healthcare as of August 18, 2026. Shares trade at $36.10, up +2.21% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Visit websiteAs of August 18, 2026, Pharvaris N.V. (PHVS) is worth $2.52B — this is its market capitalization, the total value of all its outstanding shares.
Pharvaris N.V.’s market cap is $2.52B, which ranks it #1936 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Pharvaris N.V. (PHVS) shares trade at $36.10, up 2.21% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025